Point72 Asset Management
BIO icon

Point72 Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Point72 Asset Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,195
Closed -$2.86M – 3912
2025
Q3 		$2.86M Buy
+10,195
New +$2.77M ﹤0.01% 1292
2025
Q2 		– Sell
-34,604
Closed -$8.43M – 2192
2025
Q1 		$8.43M Sell
34,604
-212,906
-86% -$64M 0.02% 744
2024
Q4 		$81.3M Sell
247,510
-2,598
-1% -$882K 0.18% 128
2024
Q3 		$83.7M Buy
+250,108
New +$79.4M 0.21% 106
2024
Q2 		– Sell
-71,400
Closed -$24.7M – 1872
2024
Q1 		$24.7M Buy
+71,400
New +$23.5M 0.06% 387
2023
Q3 		– Sell
-73,459
Closed -$27.8M – 2481
2023
Q2 		$27.8M Sell
73,459
-101,391
-58% -$41.3M 0.08% 300
2023
Q1 		$83.8M Buy
174,850
+50,424
+41% +$23.6M 0.26% 91
2022
Q4 		$52.3M Buy
124,426
+34,908
+39% +$14.1M 0.18% 144
2022
Q3 		$37.3M Sell
89,518
-52,164
-37% -$26M 0.15% 182
2022
Q2 		$70.1M Buy
141,682
+26,279
+23% +$13.7M 0.3% 78
2022
Q1 		$65M Buy
115,403
+36,345
+46% +$21.9M 0.26% 102
2021
Q4 		$59.7M Buy
79,058
+43,534
+123% +$32.6M 0.24% 104
2021
Q3 		$26.5M Buy
35,524
+23,724
+201% +$17.8M 0.12% 234
2021
Q2 		$7.6M Buy
+11,800
New +$7.18M 0.03% 513
2021
Q1 		– Sell
-6,300
Closed -$3.67M – 969
2020
Q4 		$3.67M Buy
+6,300
New +$3.59M 0.02% 634
2020
Q3 		– Sell
-14,305
Closed -$6.46M – 925
2020
Q2 		$6.46M Buy
+14,305
New +$6.31M 0.04% 432
2020
Q1 		– Sell
-34,842
Closed -$12.9M – 785
2019
Q4 		$12.9M Sell
34,842
-103,441
-75% -$36.5M 0.07% 338
2019
Q3 		$46M Sell
138,283
-146,736
-51% -$47.9M 0.28% 105
2019
Q2 		$89.1M Buy
285,019
+147,643
+107% +$44.2M 0.47% 51
2019
Q1 		$42M Buy
137,376
+10,901
+9% +$2.94M 0.19% 135
2018
Q4 		$29.4M Sell
126,475
-4,071
-3% -$1.09M 0.14% 183
2018
Q3 		$40.9M Buy
130,546
+30,943
+31% +$9.6M 0.17% 164
2018
Q2 		$28.7M Sell
99,603
-8,597
-8% -$2.37M 0.11% 224
2018
Q1 		$27.1M Buy
+108,200
New +$27.5M 0.11% 234
2017
Q2 		– Sell
-94,100
Closed -$18.8M – 836
2017
Q1 		$18.8M Buy
94,100
+81,400
+641% +$15.7M 0.1% 257
2016
Q4 		$2.31M Sell
12,700
-25,600
-67% -$4.36M 0.02% 549
2016
Q3 		$6.27M Sell
38,300
-500
-1% -$75.9K 0.04% 376
2016
Q2 		$5.55M Buy
+38,800
New +$5.53M 0.04% 405
2016
Q1 		– Sell
-58,800
Closed -$8.15M – 728
2015
Q4 		$8.15M Sell
58,800
-14,900
-20% -$2.07M 0.07% 331
2015
Q3 		$9.9M Buy
+73,700
New +$10.6M 0.08% 304

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Point72 Asset Management's BIO Position: Q4 2025 in Review

Point72 Asset Management sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2025, closing a stake of 10,195 shares — an estimated $2.86M sold.

Point72 Asset Management first reported a position in BIO in Q3 2015 and held it in 30 quarters. The position peaked at $89.1M in Q2 2019. 396 funds tracked by Wall St. Rank hold BIO as of Q4 2025.

  • Point72 Asset Management reported no remaining Bio-Rad Laboratories Class A position as of Q4 2025 after selling out during the quarter.
  • Point72 Asset Management sold 10,195 Bio-Rad Laboratories Class A shares in Q4 2025, an estimated $2.86M.
  • Point72 Asset Management first reported a position in Bio-Rad Laboratories Class A in Q3 2015 and held it in 30 quarters.
  • Point72 Asset Management's Bio-Rad Laboratories Class A position peaked at $89.1M in Q2 2019.
  • 396 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2025.

Based on Point72 Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.